To kick LIfT’s science series off, we spoke to our CEO Alex Blyth regarding what makes IMANs different to regular neutrophils, what were the breakthroughs that made the development of the IMAN technology possible and the shortcomings of current solid tumour treatments.
top of page
bottom of page